Tirzepatide TFA (LY3298176 TFA), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is under development for type 2 diabetes treatment [1].
Molecular Weight:
4927.47
Formula:
C227H349F3N48O70
Target:
Glucagon Receptor
* VAT and and shipping costs not included. Errors and price changes excepted